Print
|
Close
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Active:
Yes
Cancer Type:
Unknown Primary
NCT ID:
NCT07124078
Trial Phases:
Phase II
Protocol IDs:
INCA034176-256 (primary)
NCI-2025-07537
Eligibility:
2 - 17 Years, Male and Female
Study Type:
Treatment
Study Sponsor:
Incyte Corporation
NCI Full Details:
http://clinicaltrials.gov/show/NCT07124078
Summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in
Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior
Lines of Systemic Therapy.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.